Quercetin pharmacokinetics in humans

The purpose of this study was to examine the pharmacokinetics of quercetin aglycone as well as its conjugated metabolites and to develop a population pharmacokinetic model for quercetin that incorporates enterohepatic recirculation. The stability of quercetin in different matrices at various tempera...

Full description

Saved in:
Bibliographic Details
Published in:Biopharmaceutics & drug disposition 2008-05, Vol.29 (4), p.205-217
Main Authors: Moon, Young J., Wang, Liang, DiCenzo, Robert, Morris, Marilyn E.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Capsules
Chromatography, High Pressure Liquid
Dietary Supplements
Drug Stability
Drug Storage
enterohepatic recirculation
Female
Humans
Male
Middle Aged
pharmacokinetic model
population pharmacokinetics
quercetin
Quercetin - blood
Quercetin - pharmacokinetics
Quercetin - urine
stability
Tandem Mass Spectrometry
Temperature
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3
cites cdi_FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3
container_end_page 217
container_issue 4
container_start_page 205
container_title Biopharmaceutics & drug disposition
container_volume 29
creator Moon, Young J.
Wang, Liang
DiCenzo, Robert
Morris, Marilyn E.
description The purpose of this study was to examine the pharmacokinetics of quercetin aglycone as well as its conjugated metabolites and to develop a population pharmacokinetic model for quercetin that incorporates enterohepatic recirculation. The stability of quercetin in different matrices at various temperatures and pH, and the quercetin content of six capsules of the herbal preparation Quercetin‐500 Plus® were determined by HPLC. Subjects received quercetin 500 mg three times daily and blood and urine samples were obtained. The concentration of quercetin aglycone and conjugated metabolites were assayed using a liquid chromatography‐tandem mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis with WinNonlin. A population compartment model incorporating input from the gallbladder was developed to account for the enterohepatic recirculation observed with quercetin. The oral clearance (CL/F) was high (3.5 × 104l/h) with an average terminal half‐life of 3.5 h for quercetin. The plasma concentration versus time curves exhibited re‐entry peaks. A one‐compartment model that included enterohepatic recirculation best described the plasma data. This represents the first comprehensive evaluation of the pharmacokinetics and enterohepatic recirculation of quercetin in humans. Population pharmacokinetic models adapted for enterohepatic recirculation allowed an assessment of the magnitude and frequency of the enterohepatic recirculation process. Copyright © 2008 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/bdd.605
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69102970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69102970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3</originalsourceid><addsrcrecordid>eNp1kMtKAzEUQIMotlbxD6QL0YWM3iTzSJba2lZpq4Kiu5BkMnTsPGrSQfv3RqboymwuuRzOhYPQMYZLDECuVJpexhDtoC4GzgNg-G0XdQGHJCAJIx104Nw7AMQY433UwYyEGBjtotOnxlht1nnVXy2kLaWul3nl_9r1_W7RlLJyh2gvk4UzR9vZQy-j2-fBJJg-jO8G19NAh5hHQSiBglQm1ZFhCaachrHmnEnKtCQ0yxQYUP758xkJZRyaWHHATEeKEp7SHjprvStbfzTGrUWZO22KQlambpyIOQbCE_DgeQtqWztnTSZWNi-l3QgM4ieI8EGED-LJk62yUaVJ_7htAQ9ctMBnXpjNfx5xMxy2uqClc7c2X7-0tEsRJzSJxOt8LGaPcz6bRPdiRL8BoMV24Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69102970</pqid></control><display><type>article</type><title>Quercetin pharmacokinetics in humans</title><source>Wiley</source><creator>Moon, Young J. ; Wang, Liang ; DiCenzo, Robert ; Morris, Marilyn E.</creator><creatorcontrib>Moon, Young J. ; Wang, Liang ; DiCenzo, Robert ; Morris, Marilyn E.</creatorcontrib><description>The purpose of this study was to examine the pharmacokinetics of quercetin aglycone as well as its conjugated metabolites and to develop a population pharmacokinetic model for quercetin that incorporates enterohepatic recirculation. The stability of quercetin in different matrices at various temperatures and pH, and the quercetin content of six capsules of the herbal preparation Quercetin‐500 Plus® were determined by HPLC. Subjects received quercetin 500 mg three times daily and blood and urine samples were obtained. The concentration of quercetin aglycone and conjugated metabolites were assayed using a liquid chromatography‐tandem mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis with WinNonlin. A population compartment model incorporating input from the gallbladder was developed to account for the enterohepatic recirculation observed with quercetin. The oral clearance (CL/F) was high (3.5 × 104l/h) with an average terminal half‐life of 3.5 h for quercetin. The plasma concentration versus time curves exhibited re‐entry peaks. A one‐compartment model that included enterohepatic recirculation best described the plasma data. This represents the first comprehensive evaluation of the pharmacokinetics and enterohepatic recirculation of quercetin in humans. Population pharmacokinetic models adapted for enterohepatic recirculation allowed an assessment of the magnitude and frequency of the enterohepatic recirculation process. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0142-2782</identifier><identifier>EISSN: 1099-081X</identifier><identifier>DOI: 10.1002/bdd.605</identifier><identifier>PMID: 18241083</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Adolescent ; Adult ; Capsules ; Chromatography, High Pressure Liquid ; Dietary Supplements ; Drug Stability ; Drug Storage ; enterohepatic recirculation ; Female ; Humans ; Male ; Middle Aged ; pharmacokinetic model ; population pharmacokinetics ; quercetin ; Quercetin - blood ; Quercetin - pharmacokinetics ; Quercetin - urine ; stability ; Tandem Mass Spectrometry ; Temperature</subject><ispartof>Biopharmaceutics &amp; drug disposition, 2008-05, Vol.29 (4), p.205-217</ispartof><rights>Copyright © 2008 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3</citedby><cites>FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18241083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moon, Young J.</creatorcontrib><creatorcontrib>Wang, Liang</creatorcontrib><creatorcontrib>DiCenzo, Robert</creatorcontrib><creatorcontrib>Morris, Marilyn E.</creatorcontrib><title>Quercetin pharmacokinetics in humans</title><title>Biopharmaceutics &amp; drug disposition</title><addtitle>Biopharm. Drug Dispos</addtitle><description>The purpose of this study was to examine the pharmacokinetics of quercetin aglycone as well as its conjugated metabolites and to develop a population pharmacokinetic model for quercetin that incorporates enterohepatic recirculation. The stability of quercetin in different matrices at various temperatures and pH, and the quercetin content of six capsules of the herbal preparation Quercetin‐500 Plus® were determined by HPLC. Subjects received quercetin 500 mg three times daily and blood and urine samples were obtained. The concentration of quercetin aglycone and conjugated metabolites were assayed using a liquid chromatography‐tandem mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis with WinNonlin. A population compartment model incorporating input from the gallbladder was developed to account for the enterohepatic recirculation observed with quercetin. The oral clearance (CL/F) was high (3.5 × 104l/h) with an average terminal half‐life of 3.5 h for quercetin. The plasma concentration versus time curves exhibited re‐entry peaks. A one‐compartment model that included enterohepatic recirculation best described the plasma data. This represents the first comprehensive evaluation of the pharmacokinetics and enterohepatic recirculation of quercetin in humans. Population pharmacokinetic models adapted for enterohepatic recirculation allowed an assessment of the magnitude and frequency of the enterohepatic recirculation process. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Capsules</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Dietary Supplements</subject><subject>Drug Stability</subject><subject>Drug Storage</subject><subject>enterohepatic recirculation</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>pharmacokinetic model</subject><subject>population pharmacokinetics</subject><subject>quercetin</subject><subject>Quercetin - blood</subject><subject>Quercetin - pharmacokinetics</subject><subject>Quercetin - urine</subject><subject>stability</subject><subject>Tandem Mass Spectrometry</subject><subject>Temperature</subject><issn>0142-2782</issn><issn>1099-081X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKAzEUQIMotlbxD6QL0YWM3iTzSJba2lZpq4Kiu5BkMnTsPGrSQfv3RqboymwuuRzOhYPQMYZLDECuVJpexhDtoC4GzgNg-G0XdQGHJCAJIx104Nw7AMQY433UwYyEGBjtotOnxlht1nnVXy2kLaWul3nl_9r1_W7RlLJyh2gvk4UzR9vZQy-j2-fBJJg-jO8G19NAh5hHQSiBglQm1ZFhCaachrHmnEnKtCQ0yxQYUP758xkJZRyaWHHATEeKEp7SHjprvStbfzTGrUWZO22KQlambpyIOQbCE_DgeQtqWztnTSZWNi-l3QgM4ieI8EGED-LJk62yUaVJ_7htAQ9ctMBnXpjNfx5xMxy2uqClc7c2X7-0tEsRJzSJxOt8LGaPcz6bRPdiRL8BoMV24Q</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Moon, Young J.</creator><creator>Wang, Liang</creator><creator>DiCenzo, Robert</creator><creator>Morris, Marilyn E.</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>Quercetin pharmacokinetics in humans</title><author>Moon, Young J. ; Wang, Liang ; DiCenzo, Robert ; Morris, Marilyn E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Capsules</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Dietary Supplements</topic><topic>Drug Stability</topic><topic>Drug Storage</topic><topic>enterohepatic recirculation</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>pharmacokinetic model</topic><topic>population pharmacokinetics</topic><topic>quercetin</topic><topic>Quercetin - blood</topic><topic>Quercetin - pharmacokinetics</topic><topic>Quercetin - urine</topic><topic>stability</topic><topic>Tandem Mass Spectrometry</topic><topic>Temperature</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moon, Young J.</creatorcontrib><creatorcontrib>Wang, Liang</creatorcontrib><creatorcontrib>DiCenzo, Robert</creatorcontrib><creatorcontrib>Morris, Marilyn E.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biopharmaceutics &amp; drug disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moon, Young J.</au><au>Wang, Liang</au><au>DiCenzo, Robert</au><au>Morris, Marilyn E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quercetin pharmacokinetics in humans</atitle><jtitle>Biopharmaceutics &amp; drug disposition</jtitle><addtitle>Biopharm. Drug Dispos</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>29</volume><issue>4</issue><spage>205</spage><epage>217</epage><pages>205-217</pages><issn>0142-2782</issn><eissn>1099-081X</eissn><abstract>The purpose of this study was to examine the pharmacokinetics of quercetin aglycone as well as its conjugated metabolites and to develop a population pharmacokinetic model for quercetin that incorporates enterohepatic recirculation. The stability of quercetin in different matrices at various temperatures and pH, and the quercetin content of six capsules of the herbal preparation Quercetin‐500 Plus® were determined by HPLC. Subjects received quercetin 500 mg three times daily and blood and urine samples were obtained. The concentration of quercetin aglycone and conjugated metabolites were assayed using a liquid chromatography‐tandem mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis with WinNonlin. A population compartment model incorporating input from the gallbladder was developed to account for the enterohepatic recirculation observed with quercetin. The oral clearance (CL/F) was high (3.5 × 104l/h) with an average terminal half‐life of 3.5 h for quercetin. The plasma concentration versus time curves exhibited re‐entry peaks. A one‐compartment model that included enterohepatic recirculation best described the plasma data. This represents the first comprehensive evaluation of the pharmacokinetics and enterohepatic recirculation of quercetin in humans. Population pharmacokinetic models adapted for enterohepatic recirculation allowed an assessment of the magnitude and frequency of the enterohepatic recirculation process. Copyright © 2008 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>18241083</pmid><doi>10.1002/bdd.605</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0142-2782
ispartof Biopharmaceutics & drug disposition, 2008-05, Vol.29 (4), p.205-217
issn 0142-2782
1099-081X
language eng
recordid cdi_proquest_miscellaneous_69102970
source Wiley
subjects Adolescent
Adult
Capsules
Chromatography, High Pressure Liquid
Dietary Supplements
Drug Stability
Drug Storage
enterohepatic recirculation
Female
Humans
Male
Middle Aged
pharmacokinetic model
population pharmacokinetics
quercetin
Quercetin - blood
Quercetin - pharmacokinetics
Quercetin - urine
stability
Tandem Mass Spectrometry
Temperature
title Quercetin pharmacokinetics in humans
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A20%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quercetin%20pharmacokinetics%20in%20humans&rft.jtitle=Biopharmaceutics%20&%20drug%20disposition&rft.au=Moon,%20Young%20J.&rft.date=2008-05-01&rft.volume=29&rft.issue=4&rft.spage=205&rft.epage=217&rft.pages=205-217&rft.issn=0142-2782&rft.eissn=1099-081X&rft_id=info:doi/10.1002/bdd.605&rft_dat=%3Cproquest_cross%3E69102970%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4195-4a030abedc5e87139346c998a38ca23ffb0e0bbbb182f24a64e6b9018c5b329d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69102970&rft_id=info:pmid/18241083&rfr_iscdi=true